Abstract
Purpose
This study collected data on the use of ferric carboxymaltose (FCM) in a cancer patient population in France to evaluate the feasibility and the conditions of use of FCM in routine clinical practice beyond the limiting criteria of clinical trials.
Methods
This observational, prospective study of patients with a solid tumour or a haematological malignancy who have received treatment with FCM after 01 July 2011 evaluated data about the circumstances of iron administration, concomitant medication and laboratory tests in the period from 3 months prior to the first FCM administration (baseline) until 3 months post-baseline.
Results
Data from 367 FCM-treated patients were analysed. FCM was mainly given as a single dose at baseline (69.2 %) and without additional erythropoiesis-stimulating agent (ESA, 64.3 %). The median total iron dose was 1000 mg per patient. Median haemoglobin (Hb) levels of FCM-treated patients improved from 10.3 g/dL (interquartile range 9.5, 11.1 g/dL) at baseline to 11.8 g/dL (11.1, 13.0 g/dL) until the end of the 3-month observational period. Patients treated with FCM alone or additional ESA achieved similar median Hb increase (1.3 [0.4, 2.1] g/dL and 1.4 [0.4, 2.5] g/dL, respectively). Patients with baseline Hb up to 11.0 g/dL and serum ferritin up to 500 ng/mL and beyond achieved stable median Hb levels ≥11.0 g/dL without signs of iron overload. No severe or serious adverse reaction and no hypersensitivity reactions were reported.
Conclusions
The results of this observational study confirm the effectiveness and tolerability of FCM when given in clinical routine practice alone or in combination with an ESA.
Similar content being viewed by others
References
Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol 23:1954–1962
Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36
National Comprehensive Cancer Network Inc (2014) NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia - Version 2.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive. Accessed 28 October 2014
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116:4045–4059
Athibovonsuk P, Manchana T, Sirisabya N (2013) Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol 131:679–682
Dangsuwan P, Manchana T (2010) Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116:522–525
Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, Kim JH, Kim JW (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105:199–204
Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N (2013) Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 24:475–482
Hedenus M, Karlsson T, Ludwig H, Felder M, Roubert B, Birgegard G (2013) Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. Blood 122:3439
Ludwig H, Muldur E, Endler G, Hubl W (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886–1892
Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986
Hudis CA, Van BS, Chang J, Muenstedt K (2004) rHuEPO and treatment outcomes: the clinical experience. Oncologist 9(Suppl 5):55–69
Brownlie T, Utermohlen V, Hinton PS, Haas JD (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79:437–443
Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C (2014) Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women - PREFER a Randomized, Placebo-Controlled Study. PLoS One 9, e94217
Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G (2011) Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 118:3222–3227
Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, Osterborg A, Rzychon B, Mitchell D, Beguin Y (2014) A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 22:2197–2206
Steinmetz HT, Tsamaloukas A, Schmitz S, Wiegand J, Rohrberg R, Eggert J, Breuer F, Tessen HW, Eustermann H, Thomas L (2010) A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 19:261–269
Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611–1618
Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231–242
Munoz M, Martin-Montanez E (2012) Ferric carboxymaltose for the treatment of iron-deficiency anemia. [corrected]. Expert Opin Pharmacother 13:907–921
Ludwig H, Van BS, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306
Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142:24–38
Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011–1023
Acknowledgments
Preparation and conduct of the study have been sponsored by Vifor France SA. Data Management and biostatistical analyses were performed by ICTA PM, France, and funded by Vifor France SA. Medical writing support in the preparation of the manuscript was provided by Walter Fürst, SFL Regulatory Affairs & Scientific Communication, Switzerland, and funded by Vifor Pharma Ltd., Switzerland. The manuscript was reviewed and commented by Beate Rzychon (Vifor Pharma Ltd., Glattbrugg, Switzerland). The authors would like to thank the local investigators who actively participated in this study: Grégory Dendleux, Centre Hospitalier Pierre Oudot; Gérard Dine, Saïd Brahimi, Audrey Echegasd and Nadia Ali Amar, Centre Hospitalier Troyes; Jean-Loup Mouysset, Clinique Rambot-Provencale; Abderraouf Radji, Centre Frederic Joliot; Laurent Zelek, Kader Chouahnia, Gaetan Des Guetz, Marie-Christine Pailler and Thierry Bouillet, Hopital Avicenne; Pierre Bory, Centre Hospitalier Bastia Cedex; Mihaela Achille, Emmanuel Achille and France Campos, Institut De Cancerologie Prive De L'orangerie; Hamah Lamallem, Hopital Americain De Paris; Faress Husseini, Hopital Louis Pasteur; Claude Boiron, Anne Donnadieu, Centre Rene Huguenin; Bertrand Mennecier, Nouvel Hopital Civil; Jean-Philippe Wagner, Centre De Radiothérapie De Dunkerque; Jérôme Dauba, Hopital Layne; Isabelle Gabelle, Chu De Grenoble; Joel Castelli, Pascale Revole and Pascal Bourlet, Centre Hospitalier De Castelluccio; Younes El Masmoudi, Clinique Des Murlins; Delphine Borchiellini and Axel Leysalle, Centre Antoine Lacassagne; Dominique Jaubert, Nathalie Bonichon-Lamichhane, Hortense Laharie and Christophe Debelleix, Clinique Tivoli; Alain Zannetti and Elouen Boughalem, Centre Hospitalier Cholet Cedex; Louis-Marie Dourthe, Clinique Sainte Anne; Anne Floquet, Dominique Bechade and Marie Sire, Institut Bergonie; Isabelle Ray-Coquard, Centre Leon Berard; Jean-Pierre Crumbach, Centre Hospitalier Freyming Merlebach Cedex; Philippe Agape, Tawfiq Henni, Tahar Touahri and Jean-Francois Paitel, Centre Hospitalier Felix Guyon - Allée Des Topazes; Valérie Moulin, Aurélie Ferru, Patrick Bouchaert, Chu La Miletrie; Dominique Spaeth, Fabien Brocard and Célia Becuwe, Centre D'oncologie De Gentilly; Fabienne Watelle, Centre Hospitalier Dr Schaffner; Nadine Paillot, Caroline Cuvier, Marjorie Lallom and Sylvie Giacchotti, Hopital De Mercy; Sandrine Richard and Julie Gachet, Hopital Europeen Georges Pompidou; Marielle Guillet, Jean-Christophe Souquet and Lionel Wander, Hopital Croix Rousse; Marc Espie, Florence Coussy, Sylvie Giacchetti, Caroline Cuvier and Marjorie Lallom, Hopital Saint Louis; Karima Yakendji Bekredda, Polyclinique Sainte Marguerite; Laurent Bastit, Clinique Pasteur; Alain Saad, Selva David and Tony Nakry, Centre Hospitalier Beziers Cedex; Elisabeth Perez and Patricia Zunic, Groupe Hospitalier Sud Reunion; Jean-Philippe Metges, Institut De Cancérologie Et D'hématologie - Hôpital Morvan; Hugues Bourgeois, Clinique Victor Hugo; Philippe Laplaige, Polyclinique De Blois; Nathalie Denizon, Centre Hospitalier Le Mans Cedex 9; Michaël Finaud, Djamal Hadjadj Aoul, Velardocchio, Clinique Vert Coteau; Alain Ducolone and Elisabeth Quoix, Nouvel Hopital Civil; Jean-Pierre Lotz, Hopital Tenon; Anne Mercier-Blas and Xavier Artignan, Centre Hospitalier Prive Saint Gregoire; Jean-Louis Lacaze and Audrey Eche, Institut Claudius Regaud; and Olivier Romano, Hopital Prive La Louviere.
Conflict of interest
Alain Toledano, Elisabeth Luporsi, Kamel Laribi, Jérôme Barrière, Philippe Huot-Marchand and Roland Bugat reported no conflict of interest. Florian Scotté is consultant to Vifor Pharma. Jean François Morere received funding from Vifor Pharma. Ladan Duvillié and Victor Hugo Concas are employees of Vifor Pharma France. The authors are fully responsible for content and editorial decisions for this paper. All authors had access to the primary study data. All authors reviewed the paper and approved the final version.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Toledano, A., Luporsi, E., Morere, J.F. et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 24, 67–75 (2016). https://doi.org/10.1007/s00520-015-2728-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-015-2728-3